<HashMap><database>biostudies-literature</database><scores><citationCount>0</citationCount><reanalysisCount>0</reanalysisCount><viewCount>51</viewCount><searchCount>0</searchCount></scores><additional><submitter>Shi Q</submitter><funding>Beijing Ronghe Medical Development Foundation</funding><funding>State Key Laboratory of Analytical Chemistry for Life Sciences</funding><pagination>300060521997661</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7995454</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>49(3)</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>The objective was to derive and validate a practical scoring system for preoperative diagnosis of Xp11.2 translocation renal cell carcinoma (RCC) in adults.&lt;h4>Methods&lt;/h4>Epidemiology, symptomatology, and imaging methods were correlated between patients with common RCC and those with Xp11.2 translocation RCC using a derivation study (N = 6352) and a validation study (N = 127). Univariate analysis of risk factors was performed to derive a scoring system to predict the occurrence of Xp11.2 translocation RCC in adults. The Hosmer-Lemeshow goodness-of-fit test and receiver operating characteristic (ROC) curve were used to validate the scoring system.&lt;h4>Results&lt;/h4>Based on odd ratios, three low-risk factors (sex, gross haematuria, and intratumoural calcification) and three high-risk factors (age, unenhanced computed tomography density, and enhancement pattern) were given weighted scores of 1 and 2, respectively. Patients who scored 3 to 5 points underwent an additional magnetic resonance imaging examination. The final scoring system had a sensitivity of 81.0% and a specificity of 98.0%.&lt;h4>Conclusion&lt;/h4>We established a practical scoring system for the preoperative diagnosis of Xp11.2 translocation RCC in adults, which can be optimised through further clinical findings in the future.</pubmed_abstract><journal>The Journal of international medical research</journal><pubmed_title>A new risk-scoring system to predict Xp11.2 translocation renal cell carcinoma in adults.</pubmed_title><pmcid>PMC7995454</pmcid><funding_grant_id>5431ZZXM2004</funding_grant_id><pubmed_authors>Xu L</pubmed_authors><pubmed_authors>Zhang G</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Zhu Y</pubmed_authors><pubmed_authors>Li D</pubmed_authors><pubmed_authors>Liu N</pubmed_authors><pubmed_authors>Guo H</pubmed_authors><pubmed_authors>Shi Q</pubmed_authors><pubmed_authors>Qu F</pubmed_authors><pubmed_authors>Gan W</pubmed_authors><view_count>51</view_count></additional><is_claimable>false</is_claimable><name>A new risk-scoring system to predict Xp11.2 translocation renal cell carcinoma in adults.</name><description>&lt;h4>Objective&lt;/h4>The objective was to derive and validate a practical scoring system for preoperative diagnosis of Xp11.2 translocation renal cell carcinoma (RCC) in adults.&lt;h4>Methods&lt;/h4>Epidemiology, symptomatology, and imaging methods were correlated between patients with common RCC and those with Xp11.2 translocation RCC using a derivation study (N = 6352) and a validation study (N = 127). Univariate analysis of risk factors was performed to derive a scoring system to predict the occurrence of Xp11.2 translocation RCC in adults. The Hosmer-Lemeshow goodness-of-fit test and receiver operating characteristic (ROC) curve were used to validate the scoring system.&lt;h4>Results&lt;/h4>Based on odd ratios, three low-risk factors (sex, gross haematuria, and intratumoural calcification) and three high-risk factors (age, unenhanced computed tomography density, and enhancement pattern) were given weighted scores of 1 and 2, respectively. Patients who scored 3 to 5 points underwent an additional magnetic resonance imaging examination. The final scoring system had a sensitivity of 81.0% and a specificity of 98.0%.&lt;h4>Conclusion&lt;/h4>We established a practical scoring system for the preoperative diagnosis of Xp11.2 translocation RCC in adults, which can be optimised through further clinical findings in the future.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Mar</publication><modification>2024-02-15T15:09:47.194Z</modification><creation>2022-02-09T12:48:08.897Z</creation></dates><accession>S-EPMC7995454</accession><cross_references><pubmed>33752453</pubmed><doi>10.1177/0300060521997661</doi></cross_references></HashMap>